SpectraWAVE

Executive Summary

SpectraWAVE is a privately held medical device company based in Cambridge, MA, focused on advancing intravascular imaging and physiology for coronary artery disease. Its flagship HyperVue system uniquely integrates DeepOCT+NIRS imaging with the X1-FFR wire-free physiology solution on a single platform, providing interventional cardiologists with AI-powered, comprehensive data to optimize percutaneous coronary intervention (PCI) planning and execution. The combination of optical coherence tomography and near-infrared spectroscopy enables detailed plaque characterization, while the wire-free fractional flow reserve assessment simplifies functional lesion evaluation. This integrated approach has the potential to improve patient outcomes and procedural efficiency. Founded in 2018, SpectraWAVE operates in the competitive cardiovascular device market, targeting the growing demand for advanced, image-guided interventions. The company's technology addresses key unmet needs in PCI, such as reducing repeat revascularization and improving stent deployment accuracy. While still pre-commercial, SpectraWAVE's innovative platform and AI integration position it as a promising player in the intravascular imaging space.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for HyperVue System70% success
• Q4 2026Clinical Study Results for HyperVue60% success
• Q2 2026Series B Fundraising Round75% success